Loading
Sasanlimab is an experimental monoclonal antibody from Pfizer in phase 3 trials for bladder & urothelial cancer, aimed at PD-1 and PD-L1.
Sasanlimab (PF-06801591) is a monoclonal antibody developed by Pfizer. Its targets are PD-1 and PD-L1 (the sponsor names PD-1). The sponsor states: A monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1/PD-L2. ClinicalTrials.gov describes the intervention as: A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04165317 (A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer), in bladder & urothelial cancer. The largest, NCT04165317, plans to enrol 1068 participants (actual) with primary completion was scheduled for 2024-12-02 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.Sasanlimab binds PD-1.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Sasanlimab" OR ABSTRACT:"Sasanlimab" OR TITLE:"PF-06801591" OR ABSTRACT:"PF-06801591") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sasanlimab, not a curated reading list.
Shares PD-L1, PD-1, Bladder & urothelial cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), PD-L1 and the tag pipeline.
Shares Pfizer (incl. Seagen), Bladder & urothelial cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Bladder & urothelial cancer and the tag pipeline.